

VALUATION MULTIPLES

Forward EV / EBITDA Multiples (monthly to 30/04/2021) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of April, the sector traded on a forward EV / EBITDA multiple of 9.5x, compared to the ASX200 on 10.4x.



Average Values and Trading Multiples (values as at 10/05/2021) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2021	EV/EBIT FY2021	Price / Earnings FY2021
Aged Care	813	7.1x	11.7x	30.1x
Animal Health	163	10.4x	17.0x	18.1x
Biotech	130,137	28.3x	32.7x	41.9x
Hospitals & Clinics	45,778	10.0x	15.2x	20.3x
Healthcare	180,787	10.6x	15.5x	21.1x

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2021. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result. Composition of companies in Sector Dashboards are updated every 6 months. Most recent update: May 2021.

¹ The InterFinancial Healthcare Index set is an unweighted index comprising Healthcare sector related companies trading on the Australian Securities Exchange (ASX). Estimates are sourced from FactSet Research Systems Inc.

MERGER & ACQUISITION NEWS...



Value: AUD 9.44m

Alcidion Group Limited [ASX:ALC] has agreed to acquire **ExtraMed Limited**, the UK-based provider of patient flow management software, from **Hospedia Limited**. The purchase price represents an approximate 3.6x multiple with respect to the forecasted revenue. The acquisition will see Alcidion become the leader in the UK market for patient flow, reaching a market share of ~19% of the NHS acute care market, and providing further touchpoints from which to cross-sell the broader Alcidion product suite.



Value: Not disclosed

Belgium-based **Biobest Group** has acquired Australia-based **Biological Services**. The combination of the know-how and complementary geographic locations of these two companies now gives Biobest Group a unique position in Australia, able to offer growers varied solutions to promote more sustainable cultivation and meet the wishes of Australian consumers in search of healthier products.



Value: Not disclosed

Let's Get Care, an Australia-based home care group, has been acquired by **Quadrant Private Equity's Enrich Health Group**. Let's Get Care will combine with Enrich's existing home care provider, myHomecare Group, and become the biggest player in the Australian market looking after more than 18,000 older Australians.



Value: AUD 6m

MGC Pharmaceuticals [ASX, LSE: MXC], an Australian biopharmaceutical clinical research company, is set to acquire a 100% stake in **MediCaNL** (MCL), a company offering clinical and preclinical trial services.



Value: Not disclosed

Factor Therapeutics Limited [ASX:FTT] announced on 20 April that it has entered into a term sheet for the acquisition of **PowerLime, Inc.** and its assets. **PowerLime** holds an option to acquire land located in Early County, South Georgia in the US, considered prospective for the development of an advanced high calcium limestone project. The Acquisition is proposed to be implemented by means of a purchase agreement. The result of the Acquisition will be that **PowerLime** becomes a wholly owned subsidiary of **Factor**, with the goal of pivoting **Factor** into a resources company.

UNDER THE MICROSCOPE...

- **Imaging Associates**, an Australia-based medical imaging business is actively seeking buyers.
- **Japara Healthcare Limited** [ASX: JHC] (Japara) and major shareholders are likely to find the non-binding AUD 1.04 per share (AUD 278m) acquisition proposal from **Little Company of Mary Health Care Ltd** (Calvary) undervalued and opportunistic.
- **Advanced Human Imaging** [ASX: AHI], an Australian company engaged in early-stage technology and application development, has carried out a Binding Heads of Agreement (HOA) for a proposed acquisition of **Physimax Technologies**, an Israeli musculoskeletal assessment company.
- **Respiri Limited** [ASX: RSH] has made an off-market takeover bid for all of the fully paid ordinary shares in **Adherium Limited** [ASX: ADR].
- **Pacific Equity Partners** (PEP) has received an offer for **Evolution Healthcare** from an infrastructure investor.
- **Crescent Capital** is among final bidders in the auction for **Healthe Care**'s acute care hospitals.
- **Advanced Human Imaging** [ASX: AHI] (formerly MyFiziq Limited) has signed a letter of intent (LoI) to acquire Israeli musculoskeletal assessment company **Physimax Technologies**.
- Australian not-for-profit health care groups including **The Little Company of Mary, Calvary**, and **St John of God** are among bidders shortlisted to buy **Healthe Care**'s acute care hospitals.
- Australia's **Australian Natural Therapeutic Group** (ANTG) and Canada-based **Asterion Cannabis Inc** announced plans to merge.
- **Ramsay Health Care** [ASX: RHC] has partnered with **Pacific Equity Partners (PEP)** to bid for the Australian private hospital owner **Healthe Care**.

CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Executive Chair	(07) 3218 9122	sdoyle@interfinancial.com.au
Paul Keehan	Non-Executive Director	(07) 3218 9100	pkeehan@interfinancial.com.au
Ted Marchant	Non-Executive Director	(07) 3218 9100	tmarchant@interfinancial.com.au
Mark Steinhardt	Head of M&A	(07) 3218 9105	msteinhardt@interfinancial.com.au
Brad Shaw	Director – M&A	(07) 3218 9100	bshaw@interfinancial.com.au
David Hassum	Director	(07) 3218 9108	dhassum@interfinancial.com.au
Andrew Wheeler	Director	(07) 3218 9107	awheeler@interfinancial.com.au
Michael Kakanis	Associate Director	(07) 3218 9106	mkakanis@interfinancial.com.au
Anuk Manchanda	Associate Director	(07) 3218 9100	amanchanda@interfinancial.com.au
Lachlan O'Rourke	Analyst	(07) 3218 9104	lorourke@interfinancial.com.au

DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

Important Disclaimer – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

Disclosure. InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.

<p>InterFinancial Corporate Finance Limited ABN: 49 136 962 966 AFSL: 341675 Level 2, 201 Charlotte Street GPO Box 975 Brisbane Queensland 4001 (07) 3218 9100 admin@interfinancial.com.au www.interfinancial.com.au</p>	
---	---